To develop a therapeutic small molecule viral entry inhibitor as a medical countermeasure for filovirus infection.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93026C00012
- Awardee
-
Arisan Therapeutics Inc. UEI PYRKTQPNVJZ8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,933,547
Award facts
- Opportunity
-
- 2026 NIAID DMID Omnibus Broad Agency Announcement Pre-Solicitation · HHSNIHNIAIDBAA20251 · Posted Nov 4, 2024
- Contract value 12% obligated
-
- $2,933,547.00 Current, with exercised options
- $23,878,987.00 Potential, with all options
- Completion date 28% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 20 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Carlsbad, CA 92008, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Allergy and Infectious Diseases awarded a $23.878 million definitive contract to Arisan Therapeutics Inc. on August 3, 2026, to develop a therapeutic small molecule viral entry inhibitor as a medical countermeasure for filovirus infection.
The contract is priced on a cost-plus-fixed-fee basis with no set-aside category. Place of performance is Carlsbad, CA. The originating opportunity was posted as a pre-solicitation Broad Agency Announcement on November 4, 2024, with proposal due date February 21, 2025. The BAA sought advancement of candidate therapeutics, vaccines, and diagnostics for biodefense and emerging infectious diseases; this award addresses filovirus-related viral hemorrhagic fever medical countermeasure development. Ultimate completion date is June 30, 2027.
Quick answers
Who was awarded contract 75N93026C00012?
75N93026C00012 was awarded to Arisan Therapeutics Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 3, 2026.
How much is contract 75N93026C00012 worth?
The government has obligated $2,933,547 on 75N93026C00012. Its potential value, with all options, is $23,878,987.
Was contract 75N93026C00012 competed?
The extent of competition for 75N93026C00012 was full and open competition. The government received 20 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award